FDA APPROVES SELPERCATINIB FOR RET FUSION-POSITIVE MEDULLARY THYROID CANCER

Reuters · 09/27 19:08
FDA APPROVES SELPERCATINIB FOR RET FUSION-POSITIVE MEDULLARY THYROID CANCER